A son and daughter of unaffected parents had transfusion dependent, pyridoxinerefractory sideroblastic anaemia from birth. Their haemoglobin levels were 4-3 and 6-4 g/dl, respectively. 6-Aminolaevulinate synthase activity in erythroblasts from fractionated marrow of the sister was 135 pmol 6-aminolaevulinate formed/106 erythroblasts/hour (normal range=110-650pmol). While mutations of the erythroid-specific 6-aminolaevulinate synthase gene (ALAS2) at Xpll.21 have been reported in patients with X linked sideroblastic anaemia, sequence analysis of the ALAS2 gene in the son did not identify any mutations in the coding region, the intron/exon boundaries, or the 1 kb 5' promoter region. A useful polymorphism was found in the 3' region of the ALAS2 gene, a G to A transition, 220 nt 3' of the AATAAA polyadenylation signal. Mismatch PCR at this site and subsequent discrimination by XmnI restriction analysis of 148 alleles identified the gene frequency of this polymorphism to be 25%. Analysis of the inheritance of this intragenic polymorphism showed that the affected sibs received different maternal alleles at the ALAS2 locus, excluding mutations in this gene as the cause of their sideroblastic anaemia. Furthermore, the absence of a dimorphic erythrocyte population in the mother, coupled with the demonstration of random X inactivation in her peripheral leucocytes, showed that the mother was not the carrier of any X linked sideroblastic anaemia mutation. These results strongly suggest that the sideroblastic anaemia in this family is an autosomal recessive trait. (J Med Genet 1994;31:213-218) 
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The sideroblastic anaemias are a heterogeneous group of disorders characterised by anaemia of varying severity, ineffective erythropoiesis, increased body iron stores, and the presence of ringed sideroblasts in the bone marrow.' Sideroblastic anaemia occurs most frequently in the middle aged and elderly as an acquired defect sometimes associated with malignancy. It is also found secondary to certain drugs and toxins.' More rarely, sideroblastic anaemia is inherited as an X linked disorder which may be pyridoxine-responsive or refractory.2 Carrier females may be identified by moderately lowered haemoglobin and the presence of a dimorphic blood film owing to a bimodal erythrocyte volume distribution. (fig 1) was identified in the 3' region of the gene, 220 nucleotides 3' of the AATAAA polyadenylation signal. To identify this mutation easily, a synthetic mismatch PCR primer was constructed such that this nucleotide change would result in the creation of an XmnI restriction site in the PCR product (fig 2) . XmnI In panel A, PCR amplification of genomic DNA using the 3' primer containing the synthetic mismatch (boxed) yields a mismatch PCR product that contains an XmnI restriction site for subjects with the G to A transition. sult extends the exclusion of ALAS2 as a possible cause of sideroblastic anaemia in this family to exclusion of the X chromsome as the carrier of the mutation.
Discussion
The molecular events causing the various inherited sideroblastic anaemias are beginning to be defined. Recently, hypochromic, microcytic, pyridoxine-responsive X linked sideroblastic anaemia (XLSA) was shown to be caused by point mutations in the erythroidspecific ALAS2 gene.9"1 In addition, a macrocytic sideroblastic anaemia with vacuolised marrow precursor cells and pancreatic insuffiency was shown to be caused by mitochondrial DNA deletions.'15 Since one of the family members studied in this report had somewhat reduced marrow erythroblast ALAS activity, the family was evaluated for mutations in the ALAS2 gene.
The ALAS2 gene of the proband was normal by sequence analysis of the coding region, intron-exon junctions, and 5' and 3' flanking regions. This provided evidence for autosomal inheritance since mutations within this locus are the only described molecular defects in XLSA.11" The discovery of an informative polymorphic nucleotide change in the 3' end of the ALAS2 gene enabled conclusive demonstration that the erythroid-specific ALAS2 gene was not involved in the pathogenesis of sideroblastic anaemia in this family. The proband, case 1, was positive for the XmnI polymorphism while his affected sister, case 2, was homozygous for the wild type allele. Thus, they have clearly inherited different ALAS2 alleles from their unaffected mother, ruling out a defective ALAS2 gene as the cause of sideroblastic anaemia in this family. The slight reduction in ALAS activity observed in case 2 may be a secondary consequence of iron overload in the mitochondria.
In addition to XLSA caused by ALAS2 mutations, carrier females for X linked sideroblastic anaemia associated with ataxia also have a dimorphic erythrocyte population.'024 Methylation studies were undertaken to determine whether the expression of sideroblastic anaemia in this family could be explained by the presence of some other X linked gene and the non-random inactivation of the normal X chromosome. The polymorphic probe M27f and MspI digestion is highly informative with greater than 90% heterozygosity in females. 25 Unlike the unmethylated CpG rich islands 5' of active housekeeping genes, certain MspI sites in the M271 region are methylated on the active chromosome and unmethylated on the inactive chromosome.26 These sites occur within the extensively methylated 5' region of a LINE-1 repetitive element at the DXS255 locus.27 The X inactivation status of alleles may be determined after digestion with the methylation-sensitive restriction enzyme HpaII. Although X inactivation status was evaluated in the patients' leucocytes rather than erythroblasts, previous studies have shown that both erythroid and myeloid cells have the same isozyme ratios for X linked genes.28 After HpaII digestion, it was clear that the mother's X chromosomes were randomly inactivated as judged by the appearance of two HpaII cut bands with an intensity ratio of approximately 50/50. Since the mother's blood film did not show a dimorphic distribution and the methylation study identified random X inactivation, the sideroblastic anaemia in this family was apparently not X linked. Interestingly, the DXS255 locus, detected by the M27, probe, maps to Xpl 1. Notably, where evaluated, all of the cases listed in the table were pyridoxine-refractory. In contrast, many cases have been reported of XLSA which are pyridoxine-responsive. 4143 The first published mutation of the ALAS2 gene in a patient with XLSA was a defect in exon 9, the location of the putative pyridoxal 5'-phosphate binding site.9 This patient was pyridoxine-responsive, as was the mutant enzyme expressed in vitro. In addition, other pyridoxine-responsive patients with XLSA have recently been shown to have mutations in ALAS2.10 11 The family reported here, in addition to all of the presumed cases of autosomal inheritance of sideroblastic anaemia (table), were pyridoxine-refractory. Thus, we suggest that in cases of pyridoxine-refractory sideroblastic anaemia autosomal recessive mutations should be considered. The family we have described has a uniquely severe, pyridoxine-refractory, transFemale children with congenital sideroblastic anaemia*
